A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation.
We conducted a cost-effectiveness analysis of genetic testing for smoking cessation, based on data available from the published pharmacogenetic studies of nicotine replacement therapy and bupropion, and a previous cost-effectiveness analysis of smoking cessation treatments. We use multiparameter evidence synthesis methods to combine evidence on cessation by genotype with evidence on cessation irrespective of genotype (which can be written as a function of genotype-specific parameters). Our intention was to explore the most cost-effective approach to prescribing smoking cessation pharmacotherapy, given the hypothetical availability of a test based on a single-gene variant that has been reported to predict treatment response. We considered four types of treatment: nicotine replacement therapy (NRT) pharmacotherapy, bupropion SR pharmacotherapy, combination NRT and bupropion, and standard care as the control. Two scenarios were investigated, one in which the control represented brief advice and the other in which the control represented individual counseling. Strategies that either do not test for dopamine D2 receptor (DRD2) genotype (each individual receives the same treatment), or do test for DRD2 genotype (treatment allocated according to genotype), were evaluated. Our results indicated that the most cost-effective strategy in our hypothetical example of a single-gene test to aid prescription of smoking cessation pharmacotherapy is to prescribe both NRT and bupropion regardless of genotype, as a first-line treatment for smoking cessation. We conclude that it should not be assumed that genetic tailoring will necessarily be more cost-effective than applying the current "one-size-fits-all" model of pharmacotherapy for smoking cessation. In addition, single-gene tests are unlikely to be cost-effective, partly because the predictive value of these tests is likely to be modest.
Welton
Nicky J
NJ
Primary Care, Department, Community Based Medicine, University of Bristol, Bristol, UK. nicky.welton@bristol.ac.uk
Johnstone
Elaine C
EC
David
Sean P
SP
Munafò
Marcus R
MR
D000483:Alleles; D016642:Bupropion / Q000191:economics; D003131:Combined Modality Therapy / Q000191:economics; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D003376:Counseling / Q000191:economics; D018765:Dopamine Uptake Inhibitors / Q000191:economics; D005820:Genetic Testing / Q000191:economics* / Q000379:methods; D006801:Humans; D018803:Models, Economic; D009538:Nicotine / Q000191:economics; D011110:Polymorphism, Genetic; D017448:Receptors, Dopamine D2; D012907:Smoking / Q000235:genetics* / Q000628:therapy*; D016540:Smoking Cessation / Q000191:economics* / Q000379:methods
D018765:Dopamine Uptake Inhibitors; D017448:Receptors, Dopamine D2; D016642:Bupropion; D009538:Nicotine